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with rituximab iv preparation and administration, per treatment cycle, was about 89 
minutes versus 16 minutes estimated for sc. An average overall cost reduction of 93% 
was estimated with sc versus iv (3€ versus 45€ , respectively). DCU chair time capacity 
could be increased by 3 and 7 fold if one considers combination or maintenance 
therapy, respectively, with rituximab sc versus iv, due to SC much faster administra-
tion. Rituximab sc reduces the overall time patients spend in an infusion chair by 
95% (7 min with sc vs.143 min with iv). ConClusions: Rituximab sc formulation 
potentially offers significant resource (material and HCP time) savings, improves 
hospital organization and provides clear benefits for patients regarding time saved 
and administration convenience. Ultimately, rituximab sc increases hospital effi-
ciency that’s critical in the current economic climate.
SyStemic DiSorDerS/conDitionS – Patient-reported outcomes &  
Patient Preference Studies
PSy51
the ASSociAtion Between Severity of ‘AverAge’ PAin (nPrS) AnD the 
eQ-5D inDex in PAtientS with neuroPAthic PAin
Chambers C.1, Odeyemi I.2, Currie C.3, Poole C.D.3
1Astellas Pharma Europe Ltd., Staines, UK, 2Astellas Pharma Europe Ltd., Staines, UK, 3Cardiff 
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objeCtives: Pain is an important driver of health-related utility. Our purpose was to 
characterise the association between pain severity and the EQ-5D index. Methods: 
Paired values for the Numerical Pain Rating Scale (NPRS) average pain score (previ-
ous 24 hours) and the EQ-5D index were available from a prospective, non-inter-
ventional study of people with neuropathic pain treated with an 8% capsaicin patch 
(QutenzaTM). The NPRS records pain on an integer scale between 0 and 10 units, 
representing no pain and worst imaginable pain, respectively. The EQ-5D index 
is derived from impairment level (none/moderate/severe) across five domains 
(Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), and 
values health-related utility on a scale of 1 to 0, meaning perfect health and death, 
respectively. Generalized linear mixed models with a normal probability distribu-
tion, identity link function, and a first-order autoregressive covariance structure 
were tested to determine the relationship between EQ-5D index score (scale) and 
NPRS average 24 hour pain score (ordinal). Results: For the purposes of this pre-
liminary analysis, 170 patients with NP contributed 353 combined observations from 
baseline observation and follow-up assessments at week-8 and week-12. The GLMM 
model that best fitted the data (smallest Information criterion) had one random 
effect (subject + intercept) and one fixed effect (NPRS + intercept). The fixed-effects 
coefficients were: (Intercept) 0.728 + (NPRS1: β 0.000; 95%CI -0.0186, 0.186) + (NPRS2: 
-0.045;-0.205,0.116) + (NPRS3: -0.075;-0.227,0.078) + (NPRS4: -0.207;-0.364,-0.049) + 
(NPRS5: -0.181;-0.338,-0.024) + (NPRS6: -0.315;-0.471,-0.159) + (NPRS7: -0.323;-0.478,-
0.167) + (NPRS8: -0.458;-0.618,-0.299) + (NPRS9: -0.638;-0.825,-0.451) + (NPRS10: -0.740; 
-0.927,-0.553). Predicted utility was highly correlated (R2= 0.753) with observed util-
ity. Mean squared error for predicted utility was 0.033 (sd 0.052). ConClusions: 
Neuropathic pain was highly correlated with utility with a difference of around 
0.8 utility units across the NPRS range. All domains of the EQ-5D differed across 
the NPRS.
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meASuring ProS thAt mAtter to BAriAtric AnD BoDy contouring 
Surgery: the BoDy-Q
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objeCtives: Health care payers are interested in funding bariatric surgery because 
it resolves a range of obesity-related health problems. However, following weight 
loss, many patients are left with unsightly excesses of skin and require body-con-
touring surgery. Our team has developed a new PRO instrument (i.e., the BODY-Q) 
to measure satisfaction and quality of life of bariatric and body-contouring surgery 
patients. Unlike existing PRO instruments, the BODY-Q is composed of scales that 
measure appearance-related concerns, which is an important reason why patients 
seek treatment. The BODY-Q also stands apart as it the only PRO instrument designed 
to measure change in patients concerns throughout the entire weight loss jour-
ney. Methods: We followed international guidelines for the development of a PRO 
instrument. This abstract presents Phase I results, i.e., qualitative phase. Patient 
stories were used to develop a conceptual framework covering the key concerns of 
patients, and to develop a set of preliminary items. Items were grouped into clinically 
meaningful scales and instructions and four-point response options were developed. 
The scales were refined by obtaining feedback from a sample of surgical experts and 
patients. Results: From 59 patient interviews, we developed a conceptual frame-
work. Over 3,500 preliminary items were developed and used to inform the following 
17 independently functioning scales: 1) appearance scales measuring the body, abdo-
men, upper arms, buttocks, inner thighs, hip and outer thighs, skin and scars; 2) qual-
ity of life scales measuring body image, sexual, psychological and social wellbeing, 
physical function and symptoms; and 3) process of care scales measuring satisfaction 
with information, doctor and office staff. ConClusions: Phase II involves a multi-
centered field-test in Canada and the USA. Rasch Measurement Theory analysis will 
be used to determine which items to retain in each scale based on their performance 
against a standard set of psychometric criteria.
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its ethical and social values, supplies plasma at a lower or comparable cost than 
commercially available.
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objeCtives: To estimate indirect costs of systemic lupus erythematosus (SLE) in 
Poland, based on absenteeism in the workplace data derived from Department of 
Statistics of the Social Insurance Institution (ZUS). Methods: Available insurance 
information consisted of data on: (1) sick leaves, (2) short-term inability to work - on 
the basis of decisions authorizing rehabilitation services (3) long-term inability to 
work – on the basis of medical certificates awarded because of incapacity for work. 
To calculate indirect costs we used three parallel alterations of the human capital 
approach (HCA) method - based on: the average monthly gross earnings, Gross 
Domestic Product (GDP) per capita or gross value added per 1 employee (adjusted 
by a factor of marginal productivity of labor). Results: In 2010, in patients with SLE 
in Poland, sick leaves, short-term and long-term inability to work were responsible 
for: 1897, 596 and 27 012 months of absenteeism, in 1600, 112 and 2481 persons, 
respectively. The total number of 2459 years of lost productivity corresponded to 
indirect costs of: 100,421,579 PLN, 97,215,041 PLN or 161,743,804 PLN, based on 
average earnings, GDP per capita or adjusted gross value added per employee, 
respectively. ConClusions: Two of the three approaches, in addition - the most 
frequently mentioned in the literature, indicated the indirect costs of systemic lupus 
erythematosus in Poland at around 100 million PLN per year. Our estimates of indi-
rect costs may be undervalued because it did not include the cost of lost productivity 
due to premature mortality in the course of SLE, and the costs associated with a 
reduction in the efficiency of the work done despite of the disease (preseenteism).
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objeCtives: TTR amyloidosis, a progressive, degenerative ultra-rare genetic disease, 
can cause familial amyloid polyneuropathy (TTR-FAP) and cardiomyopathy (TTR-CM), 
requiring substantial caregiver support. This study evaluated the burden of illness 
on patients’ and caregivers’ work productivity, health care resource use (HCRU), and 
health-related quality of life (HRQoL). Methods: An online survey including the 
Work Productivity & Activity Impairment (WPAI) questionnaire, EQ-5D, & HCRU ques-
tions recruited TTR-FAP and TTR-CM patients and caregivers through two U.S.-based 
patient advocacy groups. Results: Thirty-three TTR patients (26 males) and 18 car-
egivers (7 males) completed the survey. Most were aged over 60; mean disease dura-
tion was approximately 6 years (patients) or 5 years (caregivers with disease). Most 
patients and caregivers had a college degree. Generally caregivers (77.8%) were the 
primary caregiver for their patient; 61.1% also had amyloidosis. Unemployment was 
high in patients with TTR-FAP (42.9%), TTR-CM (60.0%), both TTR-FAP/CM (71.4%); only 
33.3% of caregivers reported working part/full-time. Employment was highest for TTR-
FAP patients (n= 10), yet 11.8% missed work, 32.2% were impaired at work and 38.5% 
reported overall work impairment due to TTR. Liver transplant, the primary treatment 
option, occurred in 42.4% patients and 18.2% caregivers with disease. A majority of 
patients reported outpatient visits to health care providers in the past 3 months for 
disease: 85.7% TTR-FAP, 100% TTR-CM, and 85.7% for TTR-FAP/CM. Hospitalization 
rates ranged from 14.3-30.0% across all patient groups, with 14.3-23.8% for emer-
gency visits. EQ-5D Index scores for patients were 0.80 (SD= 0.14) with transplant, 
and 0.68 (SD= 0.16) without transplant. Caregivers with disease and transplant had 
lower EQ-5D Index scores (M= 0.14, SD= 0.35) than those without transplant (M= 0.41, 
SD= 0.32). The pattern was similar for EQ-5D VAS results for patient and caregiver 
groups. ConClusions: TTR amyloidosis is associated with substantial disruption 
in employment rates, work productivity, high levels of resource use, and poor HRQoL 
for patients and caregivers.
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Pereira C.1, Santos A.2
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objeCtives: Determine the costs associated with rituximab intravenous (iv) prepa-
ration and administration in follicular non-Hodgkin lymphoma (NHL) and estimate 
the difference versus rituximab subcutaneous (sc) formulation, considering material 
resources (MR) consumption and health care professionals (HCP) time spent in each 
procedure. Patient’s and chair time savings in hospital Day Care Unit (DCU) were 
also estimated. Methods: Rituximab iv data was collected, between November 
2012 and January 2013, through face to face interviews with pharmacists and DCU 
nurses responsible for the preparation and administration in each hospital. The HCP 
time cost was calculated by multiplying their income per hour by the average time 
spent on each procedure; MR costs were determined based in official databases or 
in “table values” provided by the manufacturers. Rituximab sc administration time 
was based in the respective pivotal clinical trial - SABRINA (BO22334). Results: 
Ten hospitals from mainland Portugal were included, with a weekly average of 7 
NHL patients treated with rituximab iv. The HCP average overall active time spent 
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A SyStemAtic review on the effect of BehAviorAl verSuS SurgicAl 
intervention on oBeSe PAtientS’ PSychologicAl well-Being
Fortier K.J., Kiss N.
Oxford Outcomes, Morristown, NJ, USA
objeCtives: Approximately 400 million people worldwide are considered obese as 
defined by the World Health Organization. In Europe, 15.5% of adults have a body 
mass index of ≥ 30 kg/m2. Diabetes, heart disease, and stroke, are among the most 
common obesity-related comorbidities. Furthermore, obesity has also been found 
to cause depression and emotional distress, negatively affecting the quality of life 
of obese patients. With obesity at the forefront of many social and health care dia-
logues, treatment guidelines currently suggest exercise (often linked with changes 
in diet) or weight loss surgery to effectively treat obesity. This review seeks to under-
stand which of these two types of interventions, exercise or surgical, have a greater 
impact on obese patients’ emotional and psychological well-being. Methods: A 
systematic review of peer-reviewed literature was conducted to identify RCTs and 
observational studies that measure any type of emotional or psychological change 
in patients who underwent either of the interventions of interest for weight loss: 
exercise or weight loss surgery. Embase and Medline databases were searched for 
articles published from 2004 to 2013. Search terms were used to identify studies 
that assessed psychological well-being of obese patients who either exercised or 
underwent weight loss surgery. Results: The search identified 40 studies, of which 
11 measured relevant interventions and measures of psychological well-being. Of 
those, 9 investigated patients undergoing bariatric surgery, while only 2 explored 
exercise interventions. All of the studies indicated improvements in patients’ emo-
tional health, except for 1 bariatric surgery study, where patients were shown to 
have no change in symptoms after weight loss plateaued. ConClusions: While 
both interventions, when they lead to weight loss, seem to result in improvements 
in patients’ psychological well-being, there is limited data to conclude whether one 
intervention is more effective in improving psychological well-being. Further study 
is needed, especially for exercise interventions.
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oBeSity trenDS 2006-2012 in the uniteD StAteS: reSultS from the 
nAtionAl heAlth AnD wellneSS Survey
Pomerantz D.1, Wang Z.2, Annunziata K.3, Gupta S.1, Martinez-Triggs C.1
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objeCtives: According to the Centers for Disease Control and Prevention, there 
were dramatic increases in the obesity rates in the US since 1980s which reached 
a plateau after 20031. The objectives of this study were to examine obesity trends 
across US adults from 2006-2012 by various gender/age groups and changes in 
activity impairment. Methods: Results were from the US National Health and 
Wellness Survey, a nationally representative, online survey. Respondents were age 
≥ 18 years, and results were weighted/projected to reflect the gender, age, and race/
ethnic proportions, as determined by the Current Population Survey (US Census 
Bureau). This analysis focused on adults age ≥ 20 by BMI Class 1 (BMI> = 30 & < 35 
kg/m2), Class 2 (BMI> = 35 & < 40 kg/m2), and Class 3 (BMI> = 40 kg/m2). Activity 
impairment was assessed from the Work Productivity and Activity Impairment 
Questionnaire. Results: The proportions of adults age 20+ with Class 1, Class 2 
and Class 3 obesity levels have slowly declined from 2006 to 2012 (Class 1: 19.3% in 
2006 to 18.4% in 2012; Class 2: 9.2% in 2006 to 8.2% in 2012; Class 3: 7.3% in 2006 to 
6.7% in 2012). This is consistent across most age/gender subgroups, except in the 
group of men age 60+, which showed increases of Class 2 (7.5% to 8.2%) and Class 
3 obesity (3.7% to 4.6%); Activity impairment declined along with the decline of 
obesity prevalence (men and women), though women reported greater impairment 
than men in the corresponding BMI Class. ConClusions: The data suggested a 
slight decline in obesity prevalence and improvement in activity function in the US 
population recently. However, obesity remains a pandemic with tremendous health 
and economic burden and calls for continuous effort in education, prevention and 
management. References 1 Centers for Disease Control and Prevention. Referenced 
June 11, 2013. http://www.cdc.gov/obesity/data/facts.html
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objeCtives: To evaluate to what extent pain severity was associated with impair-
ment of regular daily activities other than paid work. Methods: Study data 
originated from a prospective, non-interventional study of people with NP treated 
with the capsaicin patch QUTENZATM. Repeated observations from baseline- and 
12-week follow-up assessments for the Numerical Pain Rating Scale (NPRS) ‘aver-
age pain in the last 24 hours’ score, and the Activity Impairment (AI) score from 
the Work Productivity Activity Index (WPAI-NP) were analysed. The NPRS sub-
jectively records pain on a scale between 0 (no pain ) and 10 (worst imaginable 
pain). The WPAI-NP Activity Impairment Index measured the extent to which NP 
affected regular daily activities from 0% (no effect) to 100% (complete prevention). 
Generalized linear mixed models (GLMM; SPSS v20), with a normal probability 
distribution, identity link function, and a first-order autoregressive covariance 
structure were tested to determine the relationship between WPAI-NP-AI (scale) 
and NPRS (ordinal). Results: A total of 171 patients with NP contributed 253 com-
bined observations from baseline and week 12 follow-up assessment. Mean age 
at baseline was 59.4 years (sd 14.9) and 44% of subjects were male. The GLMM 
model that best fitted the data (smallest information criterion) had one random 
effect (subject+intercept) and two fixed effects (Sex+NPRS+intercept). The signifi-
cant (p< 0.05) fixed-effects coefficients were: (Intercept) 14.2+(Male: β -7.0; 95%CI 
-13.5,-0.5)+(NPRS3: 24.4;9.0,39.8)+(NPRS4:9.4;13.5,45.3)+(NPRS5:36.5;21.2,51.8)+(NP
objeCtives: To identify and evaluate the published evidence base on the use of 
preference based measures for assessing haemophilia related outcomes, and to 
discuss their limitations and gaps for evidence based decision making. Methods: A 
systematic review was carried out for 25 year time period 1988 to 2013 to investigate 
preference based evaluations of treatments and/or outcomes related to haemo-
philia. The search terms included:utility, QALY, standard gamble, time-trade-off, 
contingent valuation, conjoint analysis, and discrete choice. Results: The search 
identified 22 original peer reviewed articles, covering a range of countries and treat-
ments. There were 7 cost-utility analyses, and 7 studies reporting use of the EQ 5D 
to determine utility values for haemophilia health states. Two studies, both from 
Canada, were vignette type studies that directly assessed utilities for treatment 
related health states. The EQ 5D studies produced reasonably consistent utilities, 
whereas the vignette studies produced variable results. Six studies were conjoint 
analysis and/or willingness to pay studies and focused on the value of attributes of 
new treatments. As is typical of studies in rare diseases, there were limitations in 
all studies related mainly to small sample sizes, uncontrolled designs and poten-
tially confounding factors. The main evidence gaps were a lack of preference/util-
ity data for caregivers, or the direct impact of bleeding on utilities, and only one 
study used a generic measure other than the EQ 5D (the SF-6D) to generate utilities 
for haemophilia health states. ConClusions: Given that haemophilia is a rare 
condition, there is a reasonably large evidence base of preference based studies 
for potential use in evidence based decision making. However, the limitations and 
gaps in the studies identified mean that there are still limitations in the evidence 
base to support a comprehensive assessment of the value of new interventions 
for haemophilia.
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PAtientS At the center of regulAtory DeciSionS: uSing StAteD-
Preference DAtA to helP regulAtorS AnSwer Difficult QueStionS
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objeCtives: In collaboration with FDA’s Center for Devices and Radiological 
Health (CDRH), we developed and administered a best-practice discrete-choice 
experiment (DCE) survey to elicit preferences for outcomes associated with using 
weight-loss devices to demonstrate how DCE data can help determine meaningful 
benefits for regulatory decisions involving serious side-effect risks. Methods: An 
online DCE questionnaire was administered to adult residents of the United States 
who reported having or having had a body mass index (BMI) of at least 30 kg/m2. 
Respondents evaluated constructed hypothetical weight-loss devices with different 
features identified with the help of clinicians at CDRH. Weight-loss devices were 
defined in terms of device effectiveness, device-related risks of side effects, sur-
gery requirements for implantation, and diet restrictions. An efficient experimental 
design ensured that device profiles provided the necessary statistical information to 
identify the choice-model parameters. Random-parameter choice models produced 
preference weights indicating the strength of preference for device features. These 
weights were used to calculate the maximum acceptable risk of dying or minimum 
required weight loss associated with various device profiles. Results: A total of 
540 respondents completed the online survey. Results from the study show that 
respondents had well-defined, plausible preferences for different outcomes associ-
ated with weight-loss devices. Internal validity tests, including a scope test of sensi-
tivity to absolute risk levels, indicated the data are of high quality. Preference results 
were used to construct an Excel-based tool that calculates the necessary benefits to 
offset the device-related risks with confidence intervals for any device that can be 
described by features included in the study design. ConClusions: Results confirm 
the feasibility of using DCE methods to evaluate patients’ tolerance for weight-loss 
device risks, as well as the feasibility of constructing a policy-relevant decision aid 
that makes this information accessible to regulators.
PSy55
heAlth relAteD QuAlity of life By line of therAPy in imAtiniB-
reSiStAnt or imAtiniB-intolerAnt PAtientS with chronic myeloiD 
leukemiA treAteD with BoSutiniB meASureD By eQ-5D
Whiteley J.1, Reisman A.1, Shapiro M.2
1Pfizer Inc, New York, NY, USA, 2Pfizer Inc, Cambridge, MA, USA
objeCtives: Bosutinib a dual Src/Abl tyrosine kinase inhibitor (TKI) demonstrated 
efficacy in a phase 1/2 study of patients with relapsed/refractory Chronic Myeloid 
Leukemia (CML). Health utilities were reported in the imatinib IRIS study, but there 
is limited information from relapsed/refractory CML patients. The objective was to 
evaluate the effect of bosutinib on health utilities in patients with CML after failure 
with imatinib. Methods: Evaluation of patient HRQoL was an exploratory objective 
in the clinical trial measured using the EQ-5D, which consists of 5-items: mobil-
ity, self-care, usual activities, pain/discomfort and anxiety/depression. Each item 
ranges from 1 (“no problems”) to 3 (“extreme problems”). The EQ-5D was completed 
at weeks 4, 8, 12 and every 12 weeks thereafter, as well as treatment completion 
and scored according to the UK tariff. Results: Of the N= 570 patients included 
in the trial, 288 were second line chronic phase (CP 2L) CML, 118 were third line 
CP patients (3L), 76 were accelerated phase (AP) and 64 blast phase (BP). For 2L 
patients, the mean utility score at baseline was 0.83 (SD 0.21), and was maintained 
throughout the course of the study demonstrating a significant improvement at 
week 36 (mean change from baseline 0.04, p= 0.01). For 3L patients, the mean utility 
at baseline was 0.80 (SD 0.22), and maintained throughout the study. There were no 
statistically significant differences from baseline through week 36 in health util-
ity in 3L patients. The mean utility at baseline for advanced patients was 0.78 (SD 
0.28) for AP and 0.66 (SD 0.30) for BP patients and was maintained throughout the 
study. ConClusions: These data suggest that relapsed/refractory CML patients 
treated with bosutinib maintain their quality of life throughout the trial regardless 
of the line of treatment or phase of disease. These results highlight the value of 
capturing patient HRQoL in CML treatment.
